What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to disclose WellPoint's intention to reaffirm its full-year 2011 earnings per share (EPS) guidance to securities analysts and investors, adhering to Regulation FD requirements.

What is WellPoint's reaffirmed EPS guidance for 2011?

WellPoint reaffirmed its guidance for full-year 2011 EPS to be in the range of $7.18 to $7.28 per share.

Does the guidance include any specific components like investment gains?

Yes, the reaffirmed guidance for 2011 includes an expectation of $0.28 per share in net investment gains. The company also stated that no additional investment gains or losses beyond those already recognized in the first three quarters of 2011 were anticipated.

What are the potential risks mentioned in the filing that could impact WellPoint's future results?

The filing includes a detailed 'Safe Harbor' statement outlining numerous risks. These include, but are not limited to, increased government regulation (like the Affordable Care Act), trends in healthcare costs and utilization, competitive pricing pressures, enrollment changes, risks related to Medicare and Medicaid programs, financial strength rating downgrades, litigation, information systems maintenance, and general economic downturns.

ELV 8-K: Regulation FD

Summary

This Form 8-K filing by WellPoint, Inc. (now Elevance Health) on December 9, 2011, primarily serves as a Regulation FD disclosure. The company announced that its officers would be speaking with securities analysts and investors during a period from December 9 to December 23, 2011. During these discussions, WellPoint intended to reaffirm its previously issued earnings per share (EPS) guidance for the full year 2011, projecting a range of $7.18 to $7.28 per share. This guidance notably included net investment gains of $0.28 per share and did not anticipate any additional investment gains or losses beyond those already recognized in the first three quarters of the year. This communication is important for investors as it confirms the company's near-term financial outlook for the full year 2011, providing a degree of certainty regarding expected profitability. The reaffirmation of guidance suggests confidence in the company's performance and operational execution leading into the end of the fiscal year. The filing also includes standard forward-looking statement disclaimers, outlining various risks and uncertainties that could impact actual results, such as regulatory changes (including the Affordable Care Act), healthcare cost trends, competition, and operational challenges.

Key Highlights

1WellPoint (now Elevance Health) reaffirms its full-year 2011 earnings per share (EPS) guidance of $7.18 to $7.28.
2Guidance includes $0.28 per share in net investment gains.
3No further investment gains or losses are anticipated beyond those recorded in the first three quarters of 2011.
4The reaffirmation of guidance is expected to be communicated to securities analysts and investors between December 9 and December 23, 2011.
5The filing is a Regulation FD disclosure, ensuring broad dissemination of material information.
6Includes a comprehensive 'Safe Harbor' statement detailing numerous risks and uncertainties that could affect future performance, such as regulatory changes (ACA), healthcare cost trends, and operational risks.

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Dec 9, 2011)

Summary

Key Highlights

Frequently Asked Questions